CTRI/2020/04/024938进行中（未招募）3 期
Protocol I8F-MC-GPGN(a)The Effect of Tirzepatide versus Dulaglutide on MajorAdverse Cardiovascular Events in Patients with Type 2Diabetes (SURPASS-CVOT)
Eli Lilly and Company India Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Have a diagnosis of type 2 diabetes
- •2. Have confirmed atherosclerotic cardiovascular disease
- •3. HbA1c =7.0% to =10.5%
- •4. Body mass index (BMI) =25 kilograms per meter squared (kg/m²)
排除标准
- •1. Have had a major cardiovascular event within the last 60 days
- •2. Have type 1 diabetes mellitus
- •3. Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the last 6 months
- •4. Have a history of proliferative diabetic retinopathy; or diabetic maculopathy; or non-proliferative diabetic retinopathy that requires acute treatment
- •5. Currently planning a coronary, carotid, or peripheral artery revascularization
- •6. Have a history of pancreatitis
- •7. Have a history of ketoacidosis or hyperosmolar state/coma
- •8. Have a known clinically significant gastric emptying abnormality, have undergone or plan to have during the course of the study, or chronically take drugs that directly affect gastrointestinal (GI) motility
- •9. Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
- •10. Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
研究者
相似试验
进行中（未招募）
1 期
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)Type 2 Diabetes MellitusCTIS2023-507846-96-00Eli Lilly & Co.13,299
招募中
Unknown
A Study on the Safety and Efficacy of Tirzepatide in People with Type 2 DiabetesType 2 DiabetesJPRN-UMIN000052214Kitasato University50
尚未招募
2 期
Tirzepatide in kidney transplant candidates: a pilot studyEnd-stage renal diseaseRenal and Urogenital - Kidney diseaseMetabolic and Endocrine - Metabolic disordersObesityACTRN12624000665538St Vincent's Hospital Melbourne8
进行中（未招募）
1 期
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREASURE-CKD)CTIS2023-506082-60-00Eli Lilly & Co.140
招募中
Unknown
Clinical Study on the Efficacy of Tirzepatide for Diabetes Complicated ObesityJPRN-UMIN000054143Sekino Hospital10